CNMD

+ Watchlist + Portfolio

CONMED Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $51.25
52-Week Range: $31.44 – $56.64
Market Cap: $1.54B
P/E (TTM): 27.77
EPS (TTM): 1.85
Dividend Yield: 1.56%

Advanced Metrics

Price/Book: 1.48
PEG Ratio: 1.84
Return on Equity: 5.53%
Return on Assets: 4.14%
Gross Margin: 55.58%
Operating Margin: 14.64%
Profit Margin: 4.12%
Current Ratio: 1.48
Debt/Equity: 0.80
Total Debt: $834.25M
Free Cash Flow: $131.36M
Revenue Growth: 0.30%
Earnings Growth: 11.20%
Enterprise Value: $2.33B

CNMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.05B	$1.24B	$1.31B	$1.37B
Cost of Revenue	$474.23M	$568.50M	$573.98M	$624.25M
Gross Profit	$571.25M	$676.25M	$733.03M	$750.48M
Research & Development	$47.15M	$52.60M	$54.43M	$55.88M
Selling, General & Admin	$454.04M	$503.04M	$478.28M	$591.97M
Operating Expenses	$501.19M	$555.64M	$532.71M	$647.85M
Operating Income	$70.05M	$120.60M	$200.33M	$102.62M
EBITDA	$27.56M	$192.48M	$272.18M	$176.49M
Pretax Income	-$70.86M	$80.83M	$163.03M	$71.12M
Income Tax	$9.72M	$16.37M	$30.61M	$24.06M
Net Income	-$80.58M	$64.46M	$132.42M	$47.05M
Diluted EPS	-2.68	2.04	4.25	1.51
Diluted Shares	30.04M	31.55M	31.15M	31.15M

CNMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$28.94M	$24.30M	$24.46M	$40.82M
Receivables	$191.34M	$242.28M	$237.73M	$247.83M
Inventory	$332.32M	$318.32M	$346.72M	$355.54M
Current Assets	$581.23M	$615.65M	$640.01M	$672.86M
Total Assets	$2.30B	$2.30B	$2.31B	$2.33B
Current Liabilities	$296.55M	$310.73M	$278.13M	$315.04M
Long-Term Debt	$985.08M	$973.14M	$905.07M	$834.23M
Total Debt	$1.05B	$973.85M	$905.78M	$834.94M
Total Liabilities	$1.55B	$1.47B	$1.34B	$1.29B
Retained Earnings	$412.63M	$452.53M	$560.28M	$588.77M
Shareholders' Equity	$745.54M	$834.22M	$962.68M	$1.03B
Working Capital	$284.67M	$304.92M	$361.88M	$357.82M
Net Debt	$1.03B	$949.55M	$881.32M	$794.13M

CNMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$33.37M	$125.35M	$166.97M	$170.69M
Capital Expenditure	-$21.79M	-$19.03M	-$13.08M	-$19.81M
Free Cash Flow	$11.58M	$106.32M	$153.88M	$150.88M
Depreciation & Amortisation	$69.52M	$71.87M	$71.86M	$74.28M
Stock-Based Compensation	$21.73M	$24.26M	$25.56M	$28.32M
Investing Cash Flow	-$249.53M	-$20.03M	-$13.08M	-$20.96M
Financing Cash Flow	$225.00M	-$110.43M	-$151.00M	-$135.82M
Dividends Paid	-$23.96M	-$24.50M	-$24.65M	-$24.75M
Net Change in Cash	$8.84M	-$5.12M	$2.88M	$13.91M

CNMD Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$342.35M	$337.93M	$373.20M	$317.05M	$343.49M
Cost of Revenue	$154.03M	$171.81M	$154.91M	$133.60M	$146.03M
Gross Profit	$188.32M	$166.12M	$218.28M	$183.45M	$197.46M
Research & Development	$14.14M	$13.90M	$14.90M	$16.33M	$15.50M
Selling, General & Admin	$136.02M	$140.34M	$166.76M	$141.70M	$145.55M
Operating Expenses	$150.16M	$154.24M	$181.66M	$158.03M	$161.05M
Operating Income	$38.16M	$11.88M	$36.62M	$25.41M	$36.41M
EBITDA	$56.31M	$30.49M	$55.47M	$44.25M	$58.28M
Pretax Income	$29.92M	$4.27M	$29.25M	$18.36M	$31.35M
Income Tax	$8.50M	$1.41M	$12.51M	$4.53M	$8.28M
Net Income	$21.42M	$2.86M	$16.74M	$13.83M	$23.07M
Diluted EPS	0.69	0.09	0.54	0.45	0.77
Diluted Shares	31.05M	31.05M	31.03M	30.62M	30.12M

CNMD Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$33.94M	$38.93M	$40.82M	$35.03M	$37.33M
Receivables	$234.15M	$224.94M	$247.83M	$228.66M	$239.77M
Inventory	$362.25M	$364.36M	$355.54M	$366.11M	$360.18M
Current Assets	$657.78M	$662.16M	$672.86M	$670.59M	$675.66M
Total Assets	$2.33B	$2.32B	$2.33B	$2.31B	$2.30B
Current Liabilities	$294.84M	$314.70M	$315.04M	$292.72M	$455.40M
Long-Term Debt	$881.11M	$853.01M	$834.23M	$860.16M	$657.05M
Total Debt	$881.83M	$853.75M	$834.94M	$860.87M	$834.25M
Total Liabilities	$1.33B	$1.31B	$1.29B	$1.30B	$1.26B
Retained Earnings	$575.36M	$572.03M	$588.77M	$602.59M	$625.66M
Shareholders' Equity	$1.00B	$1.01B	$1.03B	$1.02B	$1.04B
Working Capital	$362.94M	$347.46M	$357.82M	$377.88M	$220.27M
Net Debt	$847.89M	$814.82M	$794.13M	$825.84M	$796.92M

CNMD Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$29.13M	$53.69M	$46.34M	$13.47M	$37.09M
Capital Expenditure	-$5.73M	-$5.19M	-$5.11M	-$2.89M	-$2.93M
Free Cash Flow	$23.41M	$48.50M	$41.22M	$10.58M	$34.16M
Depreciation & Amortisation	$18.57M	$18.61M	$18.85M	$18.84M	$19.05M
Stock-Based Compensation	$4.90M	$4.59M	$4.97M	$5.50M	$5.23M
Investing Cash Flow	-$5.73M	-$5.19M	-$7.11M	$4.11M	$11.57M
Financing Cash Flow	-$26.53M	-$43.52M	-$37.37M	-$22.55M	-$46.23M
Dividends Paid	-$6.19M	-$6.19M	-$6.19M	$0.00	$0.00
Share Repurchases	$0.00	—	—	-$37.02M	-$6.20M
Net Change in Cash	-$3.12M	$4.97M	$1.85M	-$4.97M	$2.43M

Market Snapshot

About

CONMED Corp. is a medical technology company that develops, manufactures, and sells surgical and patient monitoring products for healthcare providers worldwide. Headquartered in Utica, New York, the company operates through two main segments: Orthopedic Surgery and General Surgery. CONMED's orthopedic products include sports medicine equipment, powered surgical instruments, and visualization systems for arthroscopic and minimally invasive procedures. The company's general surgery portfolio features surgical devices, electrosurgical generators, smoke evacuation systems, and patient monitoring equipment. CONMED serves hospitals, surgery centers, and physicians globally through direct sales forces and distributors, focusing on improving surgical outcomes and operating room efficiency.